.Nature Medicine, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of patients along with HER2+ enhanced bosom cancer cells and also energetic or even stable mind metastases presented steady intracranial activity as well as wide spread efficacy of T-DXd.